Outset Medical, Inc. (OM)
| Market Cap | 93.61M -72.8% |
| Revenue (ttm) | 117.59M +2.0% |
| Net Income | -74.85M |
| EPS | -4.15 |
| Shares Out | 18.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 525,935 |
| Open | 4.11 |
| Previous Close | 4.02 |
| Day's Range | 4.07 - 5.25 |
| 52-Week Range | 3.00 - 21.36 |
| Beta | 1.94 |
| Analysts | Buy |
| Price Target | 8.33 (+64.95%) |
| Earnings Date | Aug 5, 2026 |
About OM
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and Tablo... [Read more]
Financial Performance
In 2025, Outset Medical's revenue was $119.48 million, an increase of 5.09% compared to the previous year's $113.69 million. Losses were -$81.65 million, -36.20% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for OM stock is "Buy." The 12-month stock price target is $8.33, which is an increase of 64.95% from the latest price.
News
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
GENEVA--(BUSINESS WIRE)--OM Pharma Unveils the Largest Multi-Country Real-World Evidence Study on Broncho Vaxom® (OM 85) for RTI Prevention at EAACI 2026.
Osisko Intersects 80 Metres Averaging 1.93% Cu at Gaspé
MONTREAL, June 09, 2026 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko Metals") ( TSX: OM ; OTCQX: OMZNF ; FRANKFURT: 0B51) is pleased to announce initial results from the 2...
Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby yo...
Outset Medical Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals passing. No questions were raised by stockholders, and official voting results will be filed with the SEC.
Osisko Metals Files NI 43-101 Technical Report for the Gaspé Copper Project
TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko Metals") (TSX: OM; OTCQX: OMZNF; FRANKFURT: OB51) is pleased to announce the filing on SEDAR+ of a techni...
Osisko Metals Announces Results of Voting at 2026 Annual Meeting of Shareholders and Welcomes Keith McKay to the Board
TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (TSX:OM "Osisko" or the "Corporation") announces the results of its annual meeting of shareholders (the "Meeting") held earlier tod...
Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN JOSE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis wi...
Outset Medical Transcript: RBC Capital Markets Global Healthcare Conference 2026
Revised summary: The company is expanding recurring revenue and profitability, with strong gross margin gains and disciplined cash management. Growth drivers include a console refresh cycle and a next-gen, FDA-cleared Tablo device. 2026 guidance remains $125–$130 million, with substantial growth expected in the year's second half.
Outset Medical to Present at RBC Global Healthcare Conference
SAN JOSE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in ...
Outset Medical price target lowered to $10 from $12 at TD Cowen
TD Cowen analyst Joshua Jennings lowered the firm’s price target on Outset Medical (OM) to $10 from $12 and keeps a Buy rating on the shares.
Outset Medical price target lowered to $6 from $8 at Stifel
Stifel lowered the firm’s price target on Outset Medical (OM) to $6 from $8 and keeps a Buy rating on the shares.
Outset Medical reports Q1 EPS ($1.03), consensus (79c)
Reports Q1 revenue $27.86M, consensus $28.9M. “We delivered a solid first quarter and continued to make meaningful progress on our path to profitability, driven by disciplined execution and another qu...
Outset Medical backs FY26 revenue view $125M-$130M, consensus $126.77M
The company said, “Outset reiterated its 2026 revenue guidance of $125 million to $130 million, a 5% to 9% increase over $119.5 million in 2025, and non-GAAP gross margin guidance…
Outset Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined 6% year-over-year to $27.9M due to capital order timing, but gross margin expanded and recurring revenue remained stable. Guidance for 2026 is reaffirmed, with most growth expected in the second half, driven by next-gen Tablo and a robust pipeline.
Outset Medical Earnings release: Q1 2026
Outset Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Outset Medical Quarterly report: Q1 2026
Outset Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
Outset Medical Reports First-Quarter Results
SAN JOSE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis wi...
Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
SAN JOSE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes i...
Outset Medical Proxy statement: Proxy filing
Outset Medical filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Outset Medical Proxy statement: Proxy filing
Outset Medical filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Outset Medical Names Derick Elliott as Executive Vice President of Commercial
SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis ...
Outset Medical price target lowered to $12 from $15 at TD Cowen
TD Cowen lowered the firm’s price target on Outset Medical (OM) to $12 from $15 and keeps a Buy rating on the shares. The firm said the company’s results met…
Outset Medical price target lowered to $15 from $17 at BTIG
BTIG analyst Marie Thibault lowered the firm’s price target on Outset Medical (OM) to $15 from $17 and keeps a Buy rating on the shares. With stability in the company’s…
Outset Medical Earnings Call Transcript: Q4 2025
Revenue grew 5% in 2025 to $119.5M, with gross margin expansion and reduced cash burn. FDA clearance of the next-gen Tablo platform positions the company for further growth, with 2026 revenue guidance of $125M–$130M and continued margin improvement.
Outset Medical Annual report: Q4 2025
Outset Medical has published its Q4 2025 annual report on February 11, 2026.